Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AbCellera Biologics Inc (ABCL) vs Amcor PLC (AMCR) Price & Performance

AbCellera Biologics IncTrade

Price performance (Past 24H)

Key statistics

AbCellera Biologics Inc vs Amcor PLC — how do they compare? AbCellera Biologics Inc trades at $9.72 (market cap $2.99B), while Amcor PLC trades at $46.45 (market cap $21.92B). The key difference: Amcor PLC is far larger — about 7.3× AbCellera Biologics Inc's market cap, and Amcor PLC pays a 5.49% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.

ABCLAMCR
Market Cap
$2.99B$21.92B
Sector
HealthBasic Materials
52-Week High
$9.76$50.58
52-Week Low
$2.78$36.69
Enterprise Value
$2.58B$37.03B
Dividend Yield
5.49%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AbCellera Biologics Inc

AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.

The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.

Amcor PLC

AMCR trades at $47.11, down 1.57% today, near the consensus price target of $47.00. Recent quarters show consistent earnings beats, with Q4 2026 revenue up 26% year-over-year to $6.4 billion, driven by the Berry acquisition (PRNewsWire, Aug 12, 2026). Technical indicators signal a bullish trend, while valuation ratios like P/E of 38.07 appear elevated relative to historical margins. The company maintains a solid dividend, with a $0.65 payment scheduled for June 2026.

Outlook is cautiously optimistic given strong revenue growth and analyst buy ratings (64% consensus), but risks include high debt levels and margin pressure, with net income margin declining to 3.06% in 2025. Investors should weigh acquisition benefits against integration challenges and cyclical demand headwinds in packaging markets.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About AbCellera Biologics Inc

AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.

Read more on ABCL

About Amcor PLC

Amcor is a global plastics packaging behemoth, with global sales of USD 14.5 billion in fiscal 2022 following the acquisition of Bemis in 2019. Amcor's operations span over 40 countries globally and include significant emerging-market exposure equating to circa 20% of sales. Amcor's capabilities span flexible and rigid plastic packaging, which sell into defensive food, beverage, healthcare, household, and personal-care end markets.

Read more on AMCR